In 2025, the United States stands at a crossroads between evidence-based medicine and persistent misinformation. On one side, groundbreaking weight-loss drugs such as GLP-1 agonists are revolutionizing obesity treatment, improving cardiovascular health, and reshaping healthcare costs. On the other, Ivermectin misinformation—often tied to old pandemic...